|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Altus Pharmaceuticals Inc., of Cambridge, Mass., initiated a Phase I trial of ALTU-237, an orally delivered crystalline formulation of an oxalate-degrading enzyme. It is being developed for the treatment of hyperoxalurias and the possible prevention of recurrent kidney stones in those with a high risk or history of kidney stones. The single-center, double-blind, placebo-controlled, dose-escalating trial will evaluate safety and tolerability in 64 normal, healthy adults. A secondary objective is to assess clinical activity, as measured by changes in urinary oxalate levels in healthy adults on a controlled, high-oxalate diet, and to identify a dose for future studies.
...